Ataluren
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Duchenne Muscular Dystrophy
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Dystrophinopathy
Trial Timeline
May 20, 2012 → Jan 19, 2018
NCT ID
NCT01557400About Ataluren
Ataluren is a phase 3 stage product being developed by PTC Therapeutics for Duchenne Muscular Dystrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT01557400. Target conditions include Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Dystrophinopathy.
What happened to similar drugs?
2 of 19 similar drugs in Duchenne Muscular Dystrophy were approved
Approved (2) Terminated (8) Active (10)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04336826 | Phase 2 | Completed |
| NCT03796637 | Phase 2 | Completed |
| NCT04117880 | Phase 2 | Withdrawn |
| NCT03648827 | Phase 2 | Completed |
| NCT02819557 | Phase 2 | Completed |
| NCT02456103 | Phase 3 | Terminated |
| NCT02107859 | Phase 3 | Terminated |
| NCT02090959 | Phase 3 | Terminated |
| NCT01557400 | Phase 3 | Completed |
| NCT01247207 | Phase 3 | Completed |
| NCT01140451 | Phase 3 | Completed |
| NCT00458341 | Phase 2 | Completed |
| NCT00237380 | Phase 2 | Completed |
Competing Products
20 competing products in Duchenne Muscular Dystrophy